MTOR and adrenal cortex carcinoma: In fact, De Martino et al. recently evaluated the expression of mTOR and downstream molecules in ACC and showed activation of the pathway in a subset of tumors.[57] Nevertheless, single-agent everolimus, another mTOR inhibitor, showed no signal of clinical activity in an exploratory study of 4 patients with advanced ACC.[58]